Terms: = Lung cancer AND EML4, ENSG00000143924, 27436 AND Diagnosis
91 results:
1. lung carcinoma with diffuse cysts repeatedly misdiagnosed as pulmonary infections and lymphoid interstitial pneumonia: A case report.
Li Y; Lu J; Yuan J
Medicine (Baltimore); 2024 Feb; 103(5):e37002. PubMed ID: 38306516
[TBL] [Abstract] [Full Text] [Related]
2. Transformation of NSCLC to SCLC harboring eml4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract] [Full Text] [Related]
3. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
Sun W; Zheng J; Zhou J; Zhou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
[TBL] [Abstract] [Full Text] [Related]
4. Non-Small Cell lung cancer: Targetable Variants in Concurrent Tissue and Liquid Biopsy Testing in a North Indian Cohort.
Paturu R; Lingaiah R; Kumari N; Singh S; Krishnani N; Srivastava S; Siddiqui SH; Nath A
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3467-3475. PubMed ID: 37898852
[TBL] [Abstract] [Full Text] [Related]
5. Radiological evidence of rapid growth acceleration of a small part solid nodule found to be large-cell carcinoma of the lung.
Lu Y; Sun Z; Li H; Chen X; Li Y; Sun L; Yang F; Jiang G; Zhou J
J Cardiothorac Surg; 2023 Jul; 18(1):236. PubMed ID: 37488608
[TBL] [Abstract] [Full Text] [Related]
6. Correlation exploration among CT imaging, pathology and genotype of pulmonary ground-glass opacity.
Cai Y; Chen T; Zhang S; Tan M; Wang J
J Cell Mol Med; 2023 Jul; 27(14):2021-2031. PubMed ID: 37340599
[TBL] [Abstract] [Full Text] [Related]
7. First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews.
Wu R; Liu S; Lv G; Deng C; Wang R; Zhang S; Zhu D; Wang L; Lei Y; Luo Z
Anticancer Drugs; 2023 Feb; 34(2):294-301. PubMed ID: 36730620
[TBL] [Abstract] [Full Text] [Related]
8. lung adenocarcinoma harboring complex eml4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract] [Full Text] [Related]
9. lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report.
Wang H; Zhu S; Li Z; Qi X; Zhang L; Ke L; Lin Y
Medicine (Baltimore); 2022 Sep; 101(35):e30316. PubMed ID: 36107507
[TBL] [Abstract] [Full Text] [Related]
10. Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report.
Fang L; Ding G; Wang M; Ye Y; Yan X; Ding P; Wang J; Zhang Y
Medicine (Baltimore); 2022 Aug; 101(34):e30255. PubMed ID: 36042596
[TBL] [Abstract] [Full Text] [Related]
11. Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.
Zhang Y; Fang H; Hong J; Wang X; Wang H; Pan G
Medicine (Baltimore); 2022 Aug; 101(33):e30094. PubMed ID: 35984185
[TBL] [Abstract] [Full Text] [Related]
12. [Multiple pulmonary nodules with interstitial changes].
Yang SQ; Hao M; Gao YL; Zhang YH; Yang MF; Jin ML; Fang Q
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):783-789. PubMed ID: 35927049
[TBL] [Abstract] [Full Text] [Related]
13. Neoadjuvant ceritinib treatment in ALK-rearranged locally advanced adenosquamous carcinoma: A case report.
Mai S; Wang Y; Wang X; Yang W; Gao H; Xu Z; Xu L; Xu L; Ou Q; Chen H; Wang Z
Thorac Cancer; 2022 Aug; 13(15):2275-2278. PubMed ID: 35818908
[TBL] [Abstract] [Full Text] [Related]
14. The Change in Paradigm for NSCLC Patients with eml4-ALK Translocation.
Bearz A; De Carlo E; Del Conte A; Spina M; Da Ros V; Bertoli E; Revelant A; Stanzione B; Tirelli U
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806325
[TBL] [Abstract] [Full Text] [Related]
15. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
Xia H; Liang B; Liu G; Qi Y; Luo N; Li M
Medicine (Baltimore); 2022 Apr; 101(14):e29134. PubMed ID: 35446297
[TBL] [Abstract] [Full Text] [Related]
16. [Anaplastic lymphoma kinase-translocation renal cell carcinoma: clinical and pathological analysis].
Di SH; Wang XT; Xia QY; Lu ZF; Ma HH; Zhang RS; Wang X; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2022 Jan; 51(1):28-32. PubMed ID: 34979750
[No Abstract] [Full Text] [Related]
17. A novel
Pan X; Zhong A; Xing Y; Li X; Du H; Shi M
J Int Med Res; 2021 Sep; 49(9):3000605211044652. PubMed ID: 34590916
[TBL] [Abstract] [Full Text] [Related]
18. A novel break site of eml4-ALK report and a rare PRKAR1A-ALK report analyzed by different ALK detection platforms in non-small cell lung cancer patients.
Du X; Zhang J; Gao H; Tai Y
Thorac Cancer; 2021 Oct; 12(20):2773-2779. PubMed ID: 34490727
[TBL] [Abstract] [Full Text] [Related]
19. Relationship between clinical features and gene mutations in non-small cell lung cancer with osteoblastic bone metastasis.
Takahara Y; Nakase K; Nojiri M; Kato R; Shinomiya S; Oikawa T; Mizuno S
Cancer Treat Res Commun; 2021; 28():100440. PubMed ID: 34325210
[TBL] [Abstract] [Full Text] [Related]
20. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.
Mondaca S; Lebow ES; Namakydoust A; Razavi P; Reis-Filho JS; Shen R; Offin M; Tu HY; Murciano-Goroff Y; Xu C; Makhnin A; Martinez A; Pavlakis N; Clarke S; Itchins M; Lee A; Rimner A; Gomez D; Rocco G; Chaft JE; Riely GJ; Rudin CM; Jones DR; Li M; Shaffer T; Hosseini SA; Bertucci C; Lim LP; Drilon A; Berger MF; Benayed R; Arcila ME; Isbell JM; Li BT
Lung Cancer; 2021 Sep; 159():66-73. PubMed ID: 34311346
[TBL] [Abstract] [Full Text] [Related]
[Next]
